Biopharma is entering a new kind of “cliff”—not just patent expiration, but the operational scramble that follows it.
When loss of exclusivity hits, the market doesn’t simply get cheaper. It gets faster. Generics arrive with aggressive pricing, payers …

One-shot strategy: how to pick the right drug patent for maximum extension value
Most pharma teams treat patent term extension like an administrative afterthought—something to file, track, and hope works out.
But in a world where timelines are compress…

Drug patent litigation isn’t just about what’s claimed—it’s about what’s designed around.
In the pharmaceutical world, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisio…

Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …

Pharma has a $300+ billion problem—and it’s not just about patents. It’s about time.
In drug development, “winning” a patent is only half the battle. The other half is the calendar: when exclusivity starts, when it ends, and how much effective market l…

Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…

Pharma executives don’t lose in Eurasia because they “missed a filing.” They lose because they misunderstood the system.
If you’re building a Eurasia strategy—whether for market entry, lifecycle management, or portfolio protection—this is the part that…

Pharma patent strategy is entering a new era: stop treating every patent like a winner. Start treating it like a portfolio.
If you’re building a pharmaceutical IP strategy today, you’re probably still asking the same question—“Do we have a patent?”
B…

The clock is ticking—so why are so many commercial market access teams waiting until after the patent clock runs out?
In pharma, timing isn’t just strategy—it’s survival.
A lot of business development (BD) in commercial market access still behaves like…

Before You Launch: The Freedom-to-Operate Checklist That Can Save Your Company From a Patent “Surprise”
In pharma, the hardest part of launching isn’t manufacturing. It’s the moment you realize your product may be blocked—not by regulators, but by pate…